These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 1974858)
1. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Schmidt CJ; Black CK; Taylor VL Eur J Pharmacol; 1990 May; 181(1-2):59-70. PubMed ID: 1974858 [TBL] [Abstract][Full Text] [Related]
2. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. Stone DM; Johnson M; Hanson GR; Gibb JW J Pharmacol Exp Ther; 1988 Oct; 247(1):79-87. PubMed ID: 2902215 [TBL] [Abstract][Full Text] [Related]
3. Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat. Hekmatpanah CR; McKenna DJ; Peroutka SJ Neurosci Lett; 1989 Sep; 104(1-2):178-82. PubMed ID: 2573011 [TBL] [Abstract][Full Text] [Related]
4. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. Schmidt CJ; Abbate GM; Black CK; Taylor VL J Pharmacol Exp Ther; 1990 Nov; 255(2):478-83. PubMed ID: 1978728 [TBL] [Abstract][Full Text] [Related]
5. L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats. Schmidt CJ; Black CK; Taylor VL Eur J Pharmacol; 1991 Oct; 203(1):41-9. PubMed ID: 1686766 [TBL] [Abstract][Full Text] [Related]
6. Neurochemical basis of neurotoxicity. Gibb JW; Johnson M; Hanson GR Neurotoxicology; 1990; 11(2):317-21. PubMed ID: 1978271 [TBL] [Abstract][Full Text] [Related]